It's become a bit of a mantra that psychotropic drugs and opioids shouldn't be co‐prescribed. That shouldn't be surprising. As every reader of the Update surely knows, we are in the midst of an ...opioid overdose epidemic, with deaths involving any opioid, whether prescription or illicit, increasing by more than seven‐fold from 1999 to 2020. That's more than 564,000 deaths. For perspective: 68,630 Americans died from opioid‐involved overdoses in 2020; deaths from motor vehicle crashes that year were 38,680. Small wonder that physicians, as well as the lay public, have looked for any possible means to limit the carnage.
As in my last commentary in the March issue, three studies in this month's issue of the Update struck me as especially comment‐worthy. This time, the common thread is obvious: ketamine. It's a topic ...that reminded me of a commentary I wrote back in July 2019, one I now look back on with no small measure of chagrin…
As I perused the contents of this month's Update, three studies in particular struck me as calling out for comment. Two of them are worth noting because they are timely and, well, attention‐getting. ...The third is more conventionally notable, although as I thought about it, I realized it resonated in an unexpected way with the other two.
The end of the buprenorphine waiver Price, Lawrence H.
Psychopharmacology update,
September 2021, 2021-09-00, 20210901, Volume:
32, Issue:
9
Journal Article
